Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 5 of 13 · 376 total
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s wearable physiological‑monitoring patent was declared entirely unpatentable after Samsung’s PTAB challenge, with the Board finding the claims obvious over a combination of prior‑art references covering optical sensors, pulse‑rate modulation, spaced emitters, and reflective surfaces.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in IPR2020‑00175, with the PTAB finding all six challenged claims of the ’299 patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while the remaining claims survived.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition challenging Omni MedSci’s ’533 wearable health‑monitoring patent, arguing that all asserted claims are obvious over prior‑art references Lisogurski, Carlson and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed in an IPR against Omni MedSci’s 9,651,533 patent, with the PTAB finding all challenged claims unpatentable as obvious over Lisogurski, Carlson, and Mannheimer. The decision hinges on pulse‑rate and signal‑to‑noise teachings in the prior art.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect challenges Align Technology’s dental aligner patent in an IPR, and Align seeks to deny the Patent Owner’s Director Review request. The response argues the new RPI theory and trial‑date evidence are improper, and that the Board’s institution decision was correct.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed Align Technology’s patent on a dual‑shell dental sheet composition, finding none of the challenged claims unpatentable after a detailed obviousness analysis involving Hinz, Durasoft data sheets, and Sun.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect has filed an IPR petition seeking to invalidate Align Technology’s 11,154,384 patent covering multilayer dental aligners. The petition argues the claims are obvious over prior‑art references such as Tadros, Kalili, Porter, Wen, and Texin 990R.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating successfully convinced the PTAB to institute review on all claims, arguing that Align Technology's dental aligner patents are obvious under 35 U.S.C. §102 and §103. The Board accepted the petitioner's arguments regarding material substitutions (Tritan for polycarbonate) and combining prior art references into a multilayer device.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB decided to institute the IPR proceedings against Align Technology's patent (10973613) after Petitioner ClearCorrect demonstrated a reasonable likelihood of prevailing. The Board found that combining prior art references like Tadros, Kalili, and Texin 990R was motivated by POSITA with reasonable expectation of success.
Terumo BCT, Inc. v.Haemonetics Corporation
Haemonetics Corp. seeks Director review to vacate the institution of an IPR filed by Terumo BCT over its plasma‑apheresis patent. The Owner argues the petitioner’s inconsistent claim‑construction positions and failure to comply with 37 C.F.R. § 42.104(b)(3) warrant denial. The request cites recent Director precedents to support vacatur.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA has filed a post‑grant review petition against Smart Denture Conversions’ U.S. Patent 12,156,781 covering dental implant fasteners. The petition alleges indefiniteness, lack of written description, enablement, and obviousness over several prior‑art references. Straumann seeks institution of the review and cancellation of all 16 claims.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health and Worcester Polytechnic Institute have entered a settlement that resolves all disputes over U.S. Patent 9,713,428. The parties filed a joint motion to terminate the inter partes review, which is pending before the Board.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Court decision.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Shenzhen Root Technology Co., Ltd. successfully petitioned the PTAB to institute an IPR against Willow Blossom Holdco Limited's breast pump patent (11813381). The Board found a reasonable likelihood of unpatentability based on multiple grounds of obviousness under 35 U.S.C. § 103, citing combinations of prior art references like Chang and Fang.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
SeaSpine petitions the PTAB to invalidate a spinal‑implant patent, arguing that its claims are obvious over long‑standing screw‑thread designs disclosed in Kirschman, Higbee, Johnson, Boschert and a 2005 publication.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
The PTAB denied an IPR petition filed by SeaSpine Holdings against Roger P. Jackson because the patent owner had disclaimed all challenged claims of U.S. Patent No. 11,399,873 B2.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review on all 15 claims of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s ’291 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All 16 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim. All nine claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an inter partes review (IPR2025-01562) filed by Imperative Care against Inari Medical’s patent 11,844,921 after finding a reasonable likelihood of unpatentability.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation by Schaffer and obviousness over combinations with Hartley, Eller and Garrison. The decision hinges on the Board’s construction that the claimed filament must be flexible, which the prior art does not disclose.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted Imperative Care’s petition to institute inter partes review of Inari Medical’s hemostasis‑valve patent, finding a reasonable likelihood of unpatentability for claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of unpatentability. The petition relied on anticipation and obviousness over Garrison and other references, but lacked sufficient particularity.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Terumo BTC, Inc v.Haemonetics Corporation
Terumo BCT has filed a post‑grant review petition challenging all 30 claims of Haemonetics’ plasma‑collection patent, arguing anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The petition relies on multiple prior‑art references covering blood‑fractionation and calculation methods.
Terumo BTC, Inc v.Haemonetics Corporation
Terumo BCT has filed a corrected PGR petition challenging Haemonetics' plasma‑collection patent (US 12,324,873). The petition alleges anticipation, obviousness, lack of written description, and patent‑ineligible subject matter. The Board must decide whether to institute the review.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
Aesthetic Management Partners has petitioned the PTAB for Inter Partes Review of HydraFacial’s 9,550,052 microdermabrasion patent, asserting that all 17 claims are obvious over a combination of prior‑art devices.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.